Pharmacologic Treatment of High Cholesterol
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.558 alerts
Get alerted when Policy 5.01.558 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and site-of-service review for pharmacologic treatments used to lower cholesterol (including injectable and IV agents) for Premera members, detailing coverage criteria, dosing limits, and prior authorization/administration site requirements for adults and selected pediatric ages.
Added coverage criteria for Tryngolza (olezarsen) for the treatment of familial chylomicronemia syndrome.
Added coverage criteria for Lerochol (lerodalcibep-liga) for treatment of HeFH and hypercholesterolemia.
Added coverage criteria for Redemplo (plozasiran) for the treatment of familial chylomicronemia syndrome.
Updated age and indication criteria for multiple agents (Leqvio, Evkeeza, Praluent, Repatha, Juxtapid) and changed some indications from 'primary hyperlipidemia' to 'hypercholesterolemia'.
Updated criteria for Leqvio (inclisiran) HeFH age requirement from 18 years to 12 years or older and added coverage criteria for treatment of HoFH.
Updated Evkeeza age requirement to 1 year and clarified prior Repatha requirement for individuals aged 10 years and older.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.